| Ytd | -36.80% | |
| 1y | -64.13% |
| Open | 0.50 | Prev Close | 0.54 | Low | 0.49 | High | 0.54 | Mkt Cap | 2.44M |
| Vol | 51.23K | Avg Vol | 43.85K | EPS | -6.11 | P/E | -0.09 | Forward P/E | -0.03 |
| Beta | 1.25 | Short Ratio | 0.43 | Inst. Own | 11.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.59 | 200-d Avg | 0.81 | 1yr Est | 90.00 |
OGEN News
Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increa
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strateg
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final ac
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed with
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targe
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targe
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targe
On Tuesday, 120 companies set new 52-week lows.
On Friday morning, 446 companies hit new 52-week lows.